Neurological Surgery 脳神経外科36巻3号

2008年03月発行

連載 悪性脳腫瘍治療の今とこれから

3．脳腫瘍の遺伝子治療―ヘルペスウイルスを用いた戦略

著者： 井上亮¹² 藤木稔¹ 古林秀則¹

所属機関： ¹大分大学医学部脳神経外科 ²大分大学医学部看護学科臨床看護学講座

ページ範囲：P.265 - P.276

Ⅰ．はじめに

　原発性脳腫瘍の中でも悪性脳腫瘍，特に神経膠芽腫は今なお治療効果の向上がほとんどみられず，手術，放射線・化学療法，免疫療法などに次ぐ新たな治療法の開発が待たれるところである．

　近年の急速な分子生物学やウイルス学の進歩に伴い，遺伝子治療分野の発展もめざましいところである．これまで，レトロウイルス，アデノウイルス，アデノ随伴ウイルスなどさまざまなウイルスがベクターとして開発されてきた．

　ヘルペスウイルス（HSV）についても同様であり，その巨大な遺伝子許容量や分裂・非分裂細胞を問わない感染域の広さなど，遺伝子治療に適した特徴を有した魅力的なウイルスである．

　本稿においては，HSVを用いた遺伝子治療の最近の発展について，自験例を紹介しつつ述べる．

参考文献

1）Borén J, Lee I, Callow MJ, Rubin EM, Innerarity TL：A simple and efficient method for making site-directed mutants, deletions, and fusions of large DNA such as P1 and BAC clones. Genome Res 6：1123-1130, 1996

2）Brune W, Messerle M, Koszinowski UH：Forward with BACs. New tools for herpesvirus genomics. Trend Genet 16：254-259, 2000

3）Burton EA, Wechuck JB, Wendell SK, Goins WF, Fink DJ, Glorioso JC：Multiple applications for replication-defective herpes simplex virus vectors. Stem Cells 19：358-377, 2001

4）Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE：Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8：27-32, 1994

5）Chung RY, Saeki Y, Chiocca EA：B-myb promoter retargeting of herpes simplex virusγ34.5 gene-mediated virulence toward tumor and cycling cells. J Virol 73：7556-7564, 1999

6）Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T：Triple gene-deleted oncolytic herpes simplex virus vector double-armed with Interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.Cancer Res 65：10663-10668, 2005

7）Fukuhara H, Todo T：Oncolytic herpes simplex virus type 1 and host immune responses. Current Cancer Drug Targets 7：149-155, 2007

8）Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, Kaur B, Louis DN, Weissleder R, Caligiuri MA, Chiocca EA：Cyclophosphamide enhances gliomas virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A 103：12873-12878, 2006

9）Hibbitt OC, Wade-Martins R：Delivery of Large Genomic DNA Inserts ＞100kg Using HSV-1 Amplicons. Current Gene Ther 6：325-336, 2006

10）Hill AB, Barnett BC, McMichael AJ, McGeoch DJ：HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J Immunol 152：2736-2741, 1994

11）市川智継，佐伯嘉修，田宮　隆，E. Antonio Chiocca，大本堯史：遺伝子治療ベクターとしての単純ヘルペスウイルス．日本臨牀58：822-827, 2000

12）Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, Harch IV GR, Louis DN, Bartus RT, Hochberg FH, Chiocca EA：Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 5：881-887, 1999

13）Ino Y, Saeki Y, Fukuhara H, Todo T：Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 12：643-652, 2006

14）Inoue R, Moghaddam KA, Ranasinghe M, Saeki Y, Chiocca EA, Wade-Martins R：Infectious delivery of the 132kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced genen expression and growth suppression in glioma cells. Gene Ther 11：1195-1204, 2004

15）Jennings SR, Rice PL, Kloszewski ED, Anderson RW, Thompson DL, Tevethia SS：Effect of herpes simplex virus types 1 and 2 on surface expression of class I major histocompatibility complex antigens on infected cells. J Virol 56：757-766, 1985

16）Kambara H, Okano H, Chiocca EA, Saeki Y：An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65：2832-2839, 2005

17）Kambara H, Saeki Y, Chiocca EA：Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res 15：11255-11258, 2005

18）Kanai R, Tomita H, Hirose Y, Ohba S, Goldman S, Okano H, Kawase T, Yazaki T：Augmented therapeutic efficacy of an oncolytic herpes simplex virus type1 mutant expressing ICP34.5 under the transcriptional control of musashi 1 promoter in the treatment of malignant gliomas. Hum Gene Ther 18：63-73, 2007

19）川口　寧：遺伝子発現制御機構．日本臨牀58：779-786, 2000

20）Link CJ, Vahanian NN, Wang S：Herpes simplex amplicon vectors. Methods Mol Med 76：61-87, 2003

21）Lundstrom K：Latest development in viral vectors for gene therapy. Trends Biotechnol 21：117-122, 2003

22）Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore, Tufaro F, Martuza RL：Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant gliomas：results of a phase I trial. Gene Ther 7：867-874, 2000

23）Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM：Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252：854-856, 1991

24）Messerle M, Crnkovic I, Hammerschmidt W, Ziegler H, Koszinowski UH：Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci USA 94：14759-14763, 1997

25）Mineta T, Rabkin SD, Martuza RL：Treatment of malignant gliomas using gancyclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 54：3963-3966, 1994

26）Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL：Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1：938-943, 1995

27）Moulton T, Samara G, Chung WY, Yuan L, Desai R, Sisti M, Bruce J, Tycko B：MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 146：613-619, 1995

deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11：159-168, 2001

29）西山幸廣，村田貴之，山内洋平：単純ヘルペスウイルス遺伝子産物の機能．ウイルス51：29-36, 2001

30）西山幸廣，川口　寧：2．ヘルペスウイルスの医学的利用―遺伝子治療と癌治療への応用―ウイルス53：155-162, 2003

31）Nishiyama, Y：Herpes simplex virus gene products：the accessories reflect her lifestyle well. Rev Med Virol 14：1-14, 2004

32）Roizman B, Knipe DM ：Herpes simplex viruses and their replication. pp2399-2459 (Knipe DM, Howley PM eds：Fields Viology, 4th edition. Lippincott-Williams ＆ Wilkins, Philadelphia, PA, 2001)

33）Saeki Y, Ichikawa T, Saeki A, Chiocca EA, Tobler K, Ackermann M, Breakfield XO, Fraefel C：Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherrichia coli：rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 9：2787-2794, 1998

34）Saeki Y, FraefelC, Ichikawa T, Breakfield XO, Chiocca EA：Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 3：591-601, 2001

35）Schmidt EE, Ichimura K, Reifenberger G, Collins VP：CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54：6321-6324, 1994

36）Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, Graham FL, Beaudet AL, Kochanek S：Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet 18：180-183, 1998

37）Sharpless NE, DePinho RA：The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 9：22-30, 1999

38）Sherr CJ：The INK4a/ARF network in tumour suppression. Nature Rev Mol Cell Biol 2：731-737, 2001

)/CDKN2B (p15) gene inactivation in malignant gliomas. Acta Neuropathol 98：444-452, 1999

40）Spaete RR Frenkel N：The herpes simplex virus amplicon：a new eukaryotic defective-virus cloning-amplifying vector. Cell 30：295-304, 1982

41）Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y：Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse models. Gene Ther 13：705-714, 2006

42）Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB, Martuza RL：Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Human Gene Ther 10：2741-2755, 1999

43）Todo T, Martuza RL, Rabkin SD, Johnson PA：Oncolytic herpes simplex virus vector with enhanced MHC class 1 presentation and tumor cell killing. Proc Natl Acad Sci USA 98：6396-6401, 2001

44）藤堂具紀：腫瘍のウイルス療法：遺伝子組換え単純ヘルペスウイルスの理論と実際．実験医学20：868-875, 2002

45）Todo T：Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci 13：2060-2064, 2008

46）Varghese S, Rabkin SD：Oncolytic herpes simplex virus vectors for cancer therapy. Cancer Gene Ther 9：967-978, 2002

47）Wade-Martins R, Frampton J, JamesMR：Long-term stability of large insert genomic DNA episomal shuttle vectors in human cells. Nucleic Acids Res 27：1674-1682, 1999

48）Wade-Martins R, Smith ER, Tyminski E, Chiocca EA, Saeki Y：An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol 19：1067-1070, 2001

49）Wade-Martins R, Saeki Y, Chiocca EA：Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther 7：604-612, 2003